Examining Opioid Treatment Infrastructure Act of 2026

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9676 Introduced in House (IH)]

<DOC>

119th CONGRESS
  2d Session
                                H. R. 9676

To direct the Comptroller General of the United States to evaluate and
      report on the inpatient and outpatient treatment capacity,
availability, and needs of the United States with respect to opioid-use
                   disorders, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             July 14, 2026

  Mr. Foster introduced the following bill; which was referred to the
 Committee on Energy and Commerce, and in addition to the Committee on
 Natural Resources, for a period to be subsequently determined by the
  Speaker, in each case for consideration of such provisions as fall
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL

To direct the Comptroller General of the United States to evaluate and
      report on the inpatient and outpatient treatment capacity,
availability, and needs of the United States with respect to opioid-use
                   disorders, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Examining Opioid Treatment
Infrastructure Act of 2026''.

SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE FOR OPIOID-USE DISORDERS.

    Not later than 24 months after the date of enactment of this Act,
the Comptroller General of the United States shall initiate an
evaluation of, and submit to Congress a report on, the inpatient and
outpatient treatment capacity, availability, and needs of the United
States with respect to opioid-use disorders, including, to the extent
data are available--
            (1) the capacity of acute residential or inpatient
        detoxification programs;
            (2) the capacity of inpatient clinical stabilization
        programs, transitional residential support services, and
        residential rehabilitation programs;
            (3) the capacity of demographic specific residential or
        inpatient treatment programs, such as those designed for
        pregnant women or adolescents;
            (4) geographical differences in the availability of
        residential and outpatient treatment and recovery options
        across the continuum of care;
            (5) the availability of residential and outpatient
        treatment programs that offer treatment options based on
        reliable scientific evidence of efficacy for the treatment of
        substance-use disorders, including the use of Food and Drug
        Administration-approved medicines and evidence-based
        nonpharmacological therapies;
            (6) the number of patients in residential and specialty
        outpatient treatment services;
            (7) an assessment of the need for residential and
        outpatient treatment across the continuum of care;
            (8) the availability of residential and outpatient
        treatment programs to American Indians and Alaska Natives
        through an Indian health program (as defined by section 4 of
        the Indian Health Care Improvement Act (25 U.S.C. 1603)); and
            (9) the barriers (including technological barriers) at the
        Federal, State, and local levels to real-time reporting of de-
        identified information on drug overdoses and ways to overcome
        such barriers.
                                 <all>